Objective To investigate the clinical effect of anti-vascular endothelial growth factor (VEGF) in the treatment of retinopathy of premature infants in different regions.
Methods Clinical data of 200 premature infants with retinopathy in our hospital were retrospectively analyzed, and these patients were divided into group A (Ⅰ district, 125 cases with 232 eyes) and group B (Ⅱ district, 75 cases with 138 eyes) according to the lesion areas. The clinical efficacy was compared after anti-VEGF treatment.
Results The response rates of initial treatment, and secondary treatment of group A were 64.66%, 71.95%, respectively, which were lower than 75.36%, 94.12%, respectively, in group B (P < 0.05). The incidence of complications was 4.00% in group A and 2.67% in group B, but no significant difference was seen between two groups(P>0.05).
Conclusion VEGF treatment for premature infants with retinopathy in Ⅰ, Ⅱ lesions is safe in treatment and has better curative efficacy, but therapeutic efficacy in area Ⅰ is lower.
DownLoad: